A Psychedelic Boom? Helus Pharma's Stock Skyrockets After Stunning Analyst Upgrade

Well, what a day it’s been for Helus Pharma (NASDAQ: HELP)! The biopharmaceutical company, a name you might remember as Cybin Inc., saw its shares absolutely leap by a solid 6% on Thursday, catching the eye of many in the market. This wasn't just any ordinary bump; it followed a truly eye-popping analysis from TD Cowen, which essentially supercharged its price target for the stock.

Indeed, Ritu Baral, a respected analyst over at TD Cowen, didn't just tweak her outlook—she delivered a bombshell. Baral ratcheted up Helus Pharma's price target from a modest $8 all the way to a stunning $62. That’s nearly an eight-fold increase, if you're counting, and it certainly sent ripples through the investment community. She didn't just throw out a number either; she firmly maintained her "Buy" rating, signaling strong conviction in the company’s future prospects. For those keeping score, this implies a staggering upside potential of roughly 426% from where the stock closed just the day before.

So, what exactly sparked such a dramatic shift in perspective? It wasn't one thing, but rather a compelling confluence of factors. A major driver, it seems, is the clearer timeline emerging for Helus Pharma's star therapeutic candidate, HLP003. This is an oral therapy, a proprietary novel serotonergic agonist (NSA), which is essentially a deuterated analogue of psilocin. It's designed as an adjunctive treatment for adults grappling with major depressive disorder (MDD) who, unfortunately, haven't found adequate relief from standard antidepressants. The good news? The first pivotal late-stage (Phase 3) study, part of their PARADIGM program, finished enrollment back in July, and we're now eagerly awaiting those topline results around mid-November 2026. Oh, and did I mention HLP003 also holds the coveted Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA)? That's a big deal, often paving the way for expedited review.

Then there's the fresh leadership, a key ingredient for any company's growth story. Helus Pharma welcomed Michael Halstead as its new Chief Executive Officer earlier in August, and his arrival is certainly turning heads. Halstead isn't just any CEO; he brings a formidable track record, having previously served as President of Intra-Cellular Therapies. During his tenure there, he famously guided the company through its colossal $14.6 billion sale to Johnson & Johnson in April 2025. That's a significant feather in his cap, showcasing not only his strategic acumen but also his ability to scale a firm and successfully launch critical treatments like CAPLYTA. Investors, naturally, are hopeful he can replicate that magic at Helus Pharma.

And let's not forget the broader landscape. The psychedelic neuropsychiatry sector itself is experiencing a veritable explosion of interest and investment. We're talking about a space that has seen over $5 billion in deals just in 2025-2026 alone! Think about it: Eli Lilly acquired AtaiBeckley for up to $3.8 billion, scooping up their BPL-003 for treatment-resistant depression. Otsuka snapped up Transcend Therapeutics for $700 million, eyeing their MDMA-like drug. Even AbbVie got in on the action, securing an experimental psychedelic-based depression drug from Gilgamesh Pharmaceuticals for up to $1.2 billion. This isn't just buzz; it's serious money pouring into the promise of these novel therapies.

What's more, there’s been significant, almost unprecedented, government support. In a landmark move, President Trump signed an executive order in April 2026, titled "Accelerating Medical Treatments for Serious Mental Illness." This order is a game-changer, aiming to speed up research, regulatory reviews, and patient access for psychedelic drugs targeting severe mental health conditions. As a direct result, the FDA has been directed to award Commissioner's National Priority Vouchers to qualifying psychedelic compounds with Breakthrough Therapy Designation—which, remember, HLP003 has! This could mean review times slashed from 6-10 months down to a mere 1-2 months. The government even allocated $50 million through ARPA-H to match state investments in psychedelic research and is working on pathways for patients to access investigational drugs under the Right to Try Act. It really paints a picture of a sector gaining undeniable momentum and legitimacy.

Beyond HLP003, Helus Pharma also has HLP004 in its pipeline, currently in Phase 2 trials and targeting generalized anxiety disorder. While not the immediate focus of this upgrade, it certainly adds another layer of future potential to the company’s portfolio.

All in all, the market is clearly excited. With critical late-stage data on the horizon, a proven leader at the helm, and a rapidly evolving, well-funded, and increasingly government-supported psychedelic neuropsychiatry sector, Helus Pharma finds itself at a truly interesting inflection point. Investors will be keeping a very close watch on those HLP003 results come mid-November; it's definitely shaping up to be a pivotal time for the company and potentially, for the future of mental health treatment.